HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: Analysis by dual-color in situ hybridization

Christina B. Ching, Mahul Amin, Raymond R. Tubbs, Paul Elson, Eric Platt, Robert Dreicer, Amr Fergany, Donna E. Hansel

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting factor in cancer, although its application to urothelial carcinoma has been limited because of a low frequency of gene amplification. We evaluated HER2 protein expression and gene amplification in micropapillary carcinoma, a rare but highly aggressive variant of urothelial carcinoma by dual-color in situ hybridization. Gene amplification was defined by a HER2:CHR17 ratio of 2.2; low and high levels of amplification were further defined as 2.5 and 2.5, respectively. Immunohistochemistry was used to determine HER2 protein expression using the American Society of Clinical Oncology/College of American Pathologists Guidelines of HER2 staining. Protein expression, gene amplification, and chromosome 17 aneusomy were compared by Jonchkeere-Terpstra and Cochran-Armitage trend tests. In all, 19 of the 20 micropapillary carcinoma samples yielded usable dual-color in situ hybridization and immunohistochemistry results for evaluation. Overall, 68% (n13) demonstrated HER2 protein expression of 2 to 3 staining. Gene amplification was present in 42% of samples (n8), with 100% correlation with 2 and 3 protein expression. Gene amplification and protein expression were significantly associated (P0.01). Overall, 53% of samples (n10) had aneusomy of chromosome 17. Chromosome 17 aneusomy was present in approximately half of the samples evaluated, suggesting inherent genomic instability in this variant of urothelial carcinoma. However, increased HER2:CHR17 ratios demonstrate increased HER2 expression due to amplification in the majority of micropapillary carcinomas. These results suggest that HER2-targeted therapy may be successful on the genomic level in patients with this disease.

Original languageEnglish (US)
Pages (from-to)1111-1119
Number of pages9
JournalModern Pathology
Volume24
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

erbB-1 Genes
Gene Amplification
In Situ Hybridization
Color
Carcinoma
Chromosomes, Human, Pair 17
Proteins
Immunohistochemistry
Staining and Labeling
human ERBB2 protein
Genomic Instability
Intercellular Signaling Peptides and Proteins
Guidelines

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma : Analysis by dual-color in situ hybridization. / Ching, Christina B.; Amin, Mahul; Tubbs, Raymond R.; Elson, Paul; Platt, Eric; Dreicer, Robert; Fergany, Amr; Hansel, Donna E.

In: Modern Pathology, Vol. 24, No. 8, 01.08.2011, p. 1111-1119.

Research output: Contribution to journalArticle

Ching, Christina B. ; Amin, Mahul ; Tubbs, Raymond R. ; Elson, Paul ; Platt, Eric ; Dreicer, Robert ; Fergany, Amr ; Hansel, Donna E. / HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma : Analysis by dual-color in situ hybridization. In: Modern Pathology. 2011 ; Vol. 24, No. 8. pp. 1111-1119.
@article{4d9db7822eb34044827636764c199de6,
title = "HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: Analysis by dual-color in situ hybridization",
abstract = "Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting factor in cancer, although its application to urothelial carcinoma has been limited because of a low frequency of gene amplification. We evaluated HER2 protein expression and gene amplification in micropapillary carcinoma, a rare but highly aggressive variant of urothelial carcinoma by dual-color in situ hybridization. Gene amplification was defined by a HER2:CHR17 ratio of 2.2; low and high levels of amplification were further defined as 2.5 and 2.5, respectively. Immunohistochemistry was used to determine HER2 protein expression using the American Society of Clinical Oncology/College of American Pathologists Guidelines of HER2 staining. Protein expression, gene amplification, and chromosome 17 aneusomy were compared by Jonchkeere-Terpstra and Cochran-Armitage trend tests. In all, 19 of the 20 micropapillary carcinoma samples yielded usable dual-color in situ hybridization and immunohistochemistry results for evaluation. Overall, 68{\%} (n13) demonstrated HER2 protein expression of 2 to 3 staining. Gene amplification was present in 42{\%} of samples (n8), with 100{\%} correlation with 2 and 3 protein expression. Gene amplification and protein expression were significantly associated (P0.01). Overall, 53{\%} of samples (n10) had aneusomy of chromosome 17. Chromosome 17 aneusomy was present in approximately half of the samples evaluated, suggesting inherent genomic instability in this variant of urothelial carcinoma. However, increased HER2:CHR17 ratios demonstrate increased HER2 expression due to amplification in the majority of micropapillary carcinomas. These results suggest that HER2-targeted therapy may be successful on the genomic level in patients with this disease.",
author = "Ching, {Christina B.} and Mahul Amin and Tubbs, {Raymond R.} and Paul Elson and Eric Platt and Robert Dreicer and Amr Fergany and Hansel, {Donna E.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1038/modpathol.2011.69",
language = "English (US)",
volume = "24",
pages = "1111--1119",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma

T2 - Analysis by dual-color in situ hybridization

AU - Ching, Christina B.

AU - Amin, Mahul

AU - Tubbs, Raymond R.

AU - Elson, Paul

AU - Platt, Eric

AU - Dreicer, Robert

AU - Fergany, Amr

AU - Hansel, Donna E.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting factor in cancer, although its application to urothelial carcinoma has been limited because of a low frequency of gene amplification. We evaluated HER2 protein expression and gene amplification in micropapillary carcinoma, a rare but highly aggressive variant of urothelial carcinoma by dual-color in situ hybridization. Gene amplification was defined by a HER2:CHR17 ratio of 2.2; low and high levels of amplification were further defined as 2.5 and 2.5, respectively. Immunohistochemistry was used to determine HER2 protein expression using the American Society of Clinical Oncology/College of American Pathologists Guidelines of HER2 staining. Protein expression, gene amplification, and chromosome 17 aneusomy were compared by Jonchkeere-Terpstra and Cochran-Armitage trend tests. In all, 19 of the 20 micropapillary carcinoma samples yielded usable dual-color in situ hybridization and immunohistochemistry results for evaluation. Overall, 68% (n13) demonstrated HER2 protein expression of 2 to 3 staining. Gene amplification was present in 42% of samples (n8), with 100% correlation with 2 and 3 protein expression. Gene amplification and protein expression were significantly associated (P0.01). Overall, 53% of samples (n10) had aneusomy of chromosome 17. Chromosome 17 aneusomy was present in approximately half of the samples evaluated, suggesting inherent genomic instability in this variant of urothelial carcinoma. However, increased HER2:CHR17 ratios demonstrate increased HER2 expression due to amplification in the majority of micropapillary carcinomas. These results suggest that HER2-targeted therapy may be successful on the genomic level in patients with this disease.

AB - Human epidermal growth factor receptor-2 (HER2) is a well-recognized growth-promoting factor in cancer, although its application to urothelial carcinoma has been limited because of a low frequency of gene amplification. We evaluated HER2 protein expression and gene amplification in micropapillary carcinoma, a rare but highly aggressive variant of urothelial carcinoma by dual-color in situ hybridization. Gene amplification was defined by a HER2:CHR17 ratio of 2.2; low and high levels of amplification were further defined as 2.5 and 2.5, respectively. Immunohistochemistry was used to determine HER2 protein expression using the American Society of Clinical Oncology/College of American Pathologists Guidelines of HER2 staining. Protein expression, gene amplification, and chromosome 17 aneusomy were compared by Jonchkeere-Terpstra and Cochran-Armitage trend tests. In all, 19 of the 20 micropapillary carcinoma samples yielded usable dual-color in situ hybridization and immunohistochemistry results for evaluation. Overall, 68% (n13) demonstrated HER2 protein expression of 2 to 3 staining. Gene amplification was present in 42% of samples (n8), with 100% correlation with 2 and 3 protein expression. Gene amplification and protein expression were significantly associated (P0.01). Overall, 53% of samples (n10) had aneusomy of chromosome 17. Chromosome 17 aneusomy was present in approximately half of the samples evaluated, suggesting inherent genomic instability in this variant of urothelial carcinoma. However, increased HER2:CHR17 ratios demonstrate increased HER2 expression due to amplification in the majority of micropapillary carcinomas. These results suggest that HER2-targeted therapy may be successful on the genomic level in patients with this disease.

UR - http://www.scopus.com/inward/record.url?scp=79961030013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961030013&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.69

DO - 10.1038/modpathol.2011.69

M3 - Article

C2 - 21516078

AN - SCOPUS:79961030013

VL - 24

SP - 1111

EP - 1119

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 8

ER -